Pro-DexFRA:PDXN 63 Net Margin % is 19.74% as of Mar. 2026, which is 37% above its 10-year median of 14.38. GuruFocus rates FRA:PDXN with a GF Score™ of 63/100 and a GF Value™ of €37.92 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Pro-Dex ranks better than 84.46% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Pro-Dex's Net Income for the
three
months ended in Mar. 2026 was €3.41 Mil. Pro-Dex's Revenue for the
three
months ended in Mar. 2026 was €17.26 Mil. Therefore, Pro-Dex's net margin for the quarter that ended in Mar. 2026 was 19.74%.
The historical rank and industry rank for Pro-Dex's Net Margin % or its related term are showing as below:
FRA:PDXN'
s Net Margin % Range Over the Past 10 Years
Min: 3.95 Med: 14.38 Max: 23.17
Current: 16.08
FRA:PDXN's Net Margin % is ranked better than 84.46% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs FRA:PDXN: 16.08
Pro-Dex (FRA:PDXN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pro-Dex Net Margin % Related Terms
Pro-Dex Net Margin % Historical Data
* Premium members only.
The historical data trend for Pro-Dex's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDXN vs SMTI, UTMD, EMBC: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Pro-Dex's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pro-Dex's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (FRA:PDXN) has a Net Margin % of 19.74% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pro-Dex and its competitors. This is 37% above median its historical median of 14.38. Over the past decade, Pro-Dex's Net Margin % has ranged from 3.95 to 23.17. According to the industry distribution chart, Pro-Dex ranks #127 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 15.5%.
Is Pro-Dex's Net Margin % too high?
Pro-Dex's current Net Margin % of 19.74% is 37% above median its 10-year median of 14.38. Over the past 10 years, this metric has ranged from a low of 3.95 to a high of 23.17. The Medical Devices & Instruments industry median Net Margin % is 2.09. Pro-Dex's value of 19.74% is 844.5% above this industry median. Based on the distribution chart, Pro-Dex ranks #127 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pro-Dex has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's Net Margin % compare to SMTI and UTMD?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #127 out of 817 companies for Net Margin %. This places Pro-Dex in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.09. Pro-Dex's value of 19.74% is 844.5% above this benchmark. Historically, Pro-Dex's own Net Margin % has ranged from 3.95 to 23.17 over the past decade. While the company's 10-year median is 14.38 vs. the industry median of 2.09, Pro-Dex has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current Net Margin % of 19.74% is 844.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pro-Dex and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current Net Margin % is 19.74%, which is 37% above median its own 10-year median of 14.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (FRA:PDXN) is currently considered Significantly Overvalued. The stock's GF Value™ is €37.92, compared to a current price of €57.00 — trading 50.3% above its estimated fair value. The current Net Margin % is 19.74%, which is 37% above median its 10-year median of 14.38 and 844.5% above the Medical Devices & Instruments industry median of 2.09. Pro-Dex's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pro-Dex (FRA:PDXN), the current Net Margin % is 19.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (FRA:PDXN) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of €57.00 is trading 50.3% above its estimated GF Value™ of €37.92.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for FRA:PDXN:
Net Margin %: 19.74% (37% above median its 10-year median of 14.38)
GF Value™: €37.92 vs. price of €57.00 (50.3% above fair value)
Industry Position: 844.5% above the Medical Devices & Instruments median (#127 of 817)
No single metric tells the full story. See the FRA:PDXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
63GF Score
Get the complete analysis for FRA:PDXN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDXN has been successfully added to your 
